Oryzon Genomics

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company focused on the discovery and development of epigenetics-based therapeutics aimed at treating cancer and central nervous system (CNS) disorders. The company is advancing its clinical pipeline with two key compounds currently in Phase II trials: iadademstat, a selective LSD1 inhibitor designed for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor targeting neurological diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor that is in preclinical stages for non-oncological conditions. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, Oryzon Genomics utilizes its epigenetic platform to identify and validate biomarkers and therapeutic targets, facilitating the creation of advanced and personalized therapies.